Amplatzer™ Talisman™ PFO Occluder

AMPLATZER™ TALISMAN™
PFO OCCLUDER
STRUCTURAL INTERVENTIONS

Effective patent foramen ovale (PFO) closure is made easier with the
Amplatzer™ Talisman™ PFO Occluder.¹For patients who have experienced
a PFO-associated stroke, clinical trials have shown that they can benefit from
PFO closure.^2–4This minimally invasive procedure significantly reduces the risk
of recurrent ischemic stroke and offers an excellent safety profile.

SWITCH TO THE REFERRAL VIEW For more information specific to neurology regarding PFO closure

The Amplatzer™ Talisman™ PFO Occluder is indicated for percutaneous transcatheter closure of a PFO to reduce the risk of recurrent ischemic stroke in patients who have had an ischemic stroke due to a presumed paradoxical embolism.

Among patients with a PFO who have had an ischemic stroke, the Amplatzer™ Talisman™ PFO Occluder has demonstrated excellent safety and effectiveness in reducing the risk of recurrent stroke.

KEY BENEFITS FOR PFO PATIENTS

59% RELATIVE RISK REDUCTION IN RECURRENT ISCHEMIC STROKE⁵

LESS ANXIETY, MORE PEACE OF MIND

For patients who have experienced a PFO-associated stroke, the thought of a recurrence can generate anxiety. Determining and delivering the most effective treatment soon after a stroke is critically important to provide these patients with peace of mind.

For patients and caregivers wanting to learn more about PFO-associated stroke and PFO closure, www.PFOstroke.com is an excellent resource, including:

All about PFO and stroke
Understanding PFO treatment options
Information about PFO occluders
Resources, including FAQ and brochures

BACK TO WALKING 12 MILES PER DAY

“

As an employee of the Royal Mail postal service “I’m back on full delivery, walking nearly 12 miles a day. Now it gets to be 8:00 at night, and I’m still bouncing off the walls, full of energy. I feel that I owe everyone who was involved a massive thank you.”

Alan Butcher - England

Connext
Hub

Your ‘go to’ resource for the most up-to-date information on cardiovascular conditions and stroke prevention technologies, developed in partnership with physicians and tailored to your personal preferences.

Find out more

TV

Left Atrial Appendage Occlusion (LAAO)

Atrial Septal Defects (ASD)

Anatomical overview of the heart

Anatomical overview of the heart with focus on ASD, PFO and LAAO

Webinar on the latest clinical outcomes on PFO

Webinar PFO closure in patients >60 Years

Webinar PFO closure with Amplatzer™ Talisman™ PFO Occluder in patients >60 years

Valentina's testimonial

Valentina's PFO patient testimonial

Echo course PFO

Echo guidance for screening and interventions in PFO closure

Amplatzer™ manufacturing video: nitinol

Manufacture of Amplatzer™ occluders using nitinol wire

PFO closure animated procedure

Amplatzer™ Talisman™ PFO Occluder closure animated implantation procedure

Abbott_AlanButcher_patientstory_subtitles_HD - AHT Stroke prevention

Alan's Testimonial

Alan's PFO patient testimonial

Patent Foramen Ovale Patient Management

Christian Pristipino provides an overview of the clinical impact of updated guidance in PFO management, following publication of the European position paper.

References

Data on file at Abbott.
Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022–1032. doi.org/10.1056/NEJMoa1610057.
Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033–1042. doi.org/10.1056/NEJMoa1707404.
Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011–1021 and supplementary appendix. doi.org/10.1056/NEJMoa1705915.
Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876–885. doi.org/10.1212/WNL.0000000000009443.

59% RELATIVE RISK REDUCTION IN RECURRENT ISCHEMIC STROKE5 LESS ANXIETY, MORE PEACE OF MIND